Latest Research And Development News

Page 12 of 89
Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.
Ada Torres
Ada Torres
27 Feb 2026
Weebit Nano Limited has reported a remarkable 8-fold increase in revenue, driven by a landmark licensing agreement with Texas Instruments and significant progress in its ReRAM technology commercialisation.
Sophie Babbage
Sophie Babbage
27 Feb 2026
SomnoMed Limited has reported a return to profitability for the half-year ending December 2025, posting a $792,000 net profit after tax on the back of a 13% revenue increase. Despite the positive turnaround, the company has elected not to pay an interim dividend.
Ada Torres
Ada Torres
27 Feb 2026
Volt Group Limited reported an 8% revenue decline and a 66% drop in profit for 2025, while advancing its growth strategy through a major acquisition and share consolidation.
Victor Sage
Victor Sage
27 Feb 2026
GreenHy2 Limited narrowed its net loss by 16% in FY2025, driven by government grants and initial sales of its new sodium-ion batteries. Strategic partnerships and product diversification position the company for growth in renewable energy storage.
Maxwell Dee
Maxwell Dee
26 Feb 2026
Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.
Ada Torres
Ada Torres
26 Feb 2026
Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.
Ada Torres
Ada Torres
26 Feb 2026
Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.
Victor Sage
Victor Sage
26 Feb 2026
Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.
Ada Torres
Ada Torres
26 Feb 2026
Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.
Ada Torres
Ada Torres
26 Feb 2026
BluGlass Limited reported a 14% revenue increase to A$5.76 million and a 28% reduction in net loss to A$4.1 million for H1 FY26, bolstered by a key US Department of War contract extension and a refreshed board driving growth.
Sophie Babbage
Sophie Babbage
26 Feb 2026
Advanced Braking Technology Ltd has corrected its half-year results to reveal a robust 55.2% increase in earnings per share, alongside a strong 27% revenue growth driven by demand for its safety braking systems.
Victor Sage
Victor Sage
26 Feb 2026